Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the Ugly

Martin Kornecki, Fabian Mestmäcker, Steffen Zobel-Roos, Laura Heikaus de Figueiredo, Hartmut Schlüter and Jochen Strube

1 Institute for Separation and Process Technology, Clausthal University of Technology, Leibnizstr. 15, 38678 Clausthal-Zellerfeld, Germany; kornecki@itv.tu-clausthal.de (M.K.); mestmaecker@itv.tu-clausthal.de (F.M.); zobel-roos@itv.tu-clausthal.de (S.Z.-R.)

2 Institute of Clinical Chemistry, Department for Mass Spectrometric Proteomics, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany; l.heikaus@uke.de (L.H.d.F.); hschluet@uke.de (H.S.)

* Correspondence: strube@itv.tu-clausthal.de

Received: 17 August 2017; Accepted: 10 September 2017; Published: 16 September 2017

Abstract: Significant progress in the manufacturing of biopharmaceuticals has been made by increasing the overall titers in the USP (upstream processing) titers without raising the cost of the USP. In addition, the development of platform processes led to a higher process robustness. Despite or even due to those achievements, novel challenges are in sight. The higher upstream titers created more complex impurity profiles, both in mass and composition, demanding higher separation capacities and selectivity in downstream processing (DSP). This creates a major shift of costs from USP to DSP. In order to solve this issue, USP and DSP integration approaches can be developed and used for overall process optimization. This study focuses on the characterization and classification of host cell proteins (HCPs) in each unit operation of the DSP (i.e., aqueous two-phase extraction, integrated countercurrent chromatography). The results create a data-driven feedback to the USP, which will serve for media and process optimizations in order to reduce, or even eliminate nascent critical HCPs. This will improve separation efficiency and may lead to a quantitative process understanding. Different HCP species were classified by stringent criteria with regard to DSP separation parameters into “The Good, the Bad, and the Ugly” in terms of pI and MW using 2D-PAGE analysis depending on their positions on the gels. Those spots were identified using LC-MS/MS analysis. HCPs, which are especially difficult to remove and persistent throughout the DSP (i.e., “Bad” or “Ugly”), have to be evaluated by their ability to be separated. In this approach, HCPs, considered “Ugly,” represent proteins with a MW larger than 15 kDa and a pI between 7.30 and 9.30. “Bad” HCPs can likewise be classified using MW (>15 kDa) and pI (4.75–7.30 and 9.30–10.00). HCPs with a MW smaller than 15 kDa and a pI lower than 4.75 and higher than 10.00 are classified as “Good” since their physicochemical properties differ significantly from the product. In order to evaluate this classification scheme, it is of utmost importance to use orthogonal analytical methods such as IEX, HIC, and SEC.

Keywords: upstream; downstream; host cell protein; CHO; ATPE; iCCC

1. Introduction

The amounts of biotechnology products produced worldwide, prescription as well as over-the-counter drugs, are estimated to account for around 50% of the most successful pharmaceutical products by the year 2020 [1]. Oncology constitutes the biggest therapeutic sector, with an annual growth rate of around 12.5% and sales of approximately $83.2 billion in 2015. Among the five top-selling oncological products, three will be monoclonal antibodies by the year 2020 [2]. The manufacturing
The manufacturing process of biopharmaceuticals such as monoclonal antibodies (e.g., IgG, immunoglobulin G) is divided into upstream (USP) and downstream processing (DSP) [3–8]. The production of the monoclonal antibody in bioreactors (BR) using mammalian cells as an expression host and the separation of the liquid phase from the cells using centrifuges or filters is defined as USP [9]. The subsequent DSP is designed to separate side components like host cell proteins (HCP) or host cell DNA (hDNA) from the main component [6,7,10]. The most common unit operations used in the DSP are typically chromatography and filtration.

The commercial success of monoclonal antibodies of course led to significantly increased demand in their production scale [11]. Coping with these demands without significantly changing the approved manufacturing facilities almost forced companies to follow the route of increasing titers within the existing facilities.

Hence, compared to earlier yields of a couple of grams per liter, today antibody concentrations of up to 25 g/L can be achieved using a modified perfusion process [12,13]. Routinely, antibody concentrations of between three and five grams per liter can be generated in fed-batch processes [3,14,15]. However, increasing product titers at constant volumes due to higher cell concentrations will lead to capacity limitations in the DSP, which has to be compensated for by longer process times, higher material consumption, and corresponding costs [4]. This will significantly shift the cost of goods from the USP to the DSP [5]. Therefore, DSP technologies are required that circumvent this upcoming “downstream bottleneck,” handling high titer volumes [4,16,17].

Optimizations in the USP concepts have led to increasing product titers. Along with this, raised impurity profiles have been observed [8,9]. Various compositions of the cultivation broth present challenges in the DSP of biotechnologically produced proteins. Considering the generic platform production process for antibodies, unit operations like centrifugation, micro- and ultrafiltration, protein A affinity chromatography, two orthogonal virus inactivation steps, ion-exchange (IEX), and hydrophobic interaction chromatography (HIC) are being used [5]. For the characterization of protein purification stages, key performance parameters can be used. These are typically resolution, speed, recovery, and capacity, as seen in Figure 1.

![Figure 1](image.png)

**Figure 1.** Key performance parameters of the capture, intermediate purification, and polishing step for protein purifications according to [18].
The objectives vary depending on the purification stage in focus, and therefore generate different challenges that have to be addressed during process optimization [18]. For example, the protein A affinity chromatography, used as a capture step, will reach its capacity limitation due to increasing product titers. This can be problematic since this criterion characterizes the capture step and is one of its two objectives. Moving downstream, selectivity challenges occurring during the intermediate purification and polishing step will prevent each step from reaching one of its objectives. Selectivity challenges are going to affect the resolution in IEX and HIC separation operations when HCP resemble the product in terms of pI and hydrophobicity, respectively [12,18].

Impurities like HCPs, which resemble the desired product only in one characteristic (e.g., pI), may challenge the IEX but can probably be easily separated from the product by an additional chromatographic step (e.g., HIC). Impurities similar to the product in more than one characteristic (e.g., pI and hydrophobicity) will be troublesome during purification and polishing. Therefore, the pI and hydrophobic distribution of the impurity spectrum can negatively affect IEX and HIC separations, respectively.

Critical performance parameters regarding the separation efficiency during the capture of monoclonal antibodies using affinity chromatography are capacity limitations as well as (un-)specific HCP co-elution [19]. Consequently, new approaches and technology are needed in order to circumvent future bottlenecks and separation challenges [4].

Furthermore, the existing challenges in process engineering have worsened since regulatory agencies demand higher product quality, an advanced understanding of the process and product, as well as batch-independent product quality [20–22]. Bioprocess engineering will probably focus in regulated industries on quality by design and process analytical technology mechanisms, in order to design, analyze, and control manufacturing processes [23]. This shall lead to improved process control by knowledge-based and statistical methods, which ultimately guarantees the process' robustness.

For example, monoclonal antibodies and fragments represent an interesting group of biopharmaceuticals due to their broad field of application (e.g., analysis or diagnostic). Those glycoproteins are structurally complex and differ in various formats, as can be seen in Figure 2. IgG is the most common format as a biopharmaceutical drug [2].

Figure 2. Various formats of recombinant antibodies [24].
The post-translational modifications, especially glycosylations, of these proteins are of utmost importance for their correct function [20]. The immense diversity of glycosylation patterns impacts the functionality, immunogenicity, and pharmacokinetics of the antibody [24,25]. Due to this, posttranslational modifications should be considered critical quality attributes (CQA) and verified throughout the manufacturing of monoclonal antibodies [26–30]. Antibody N-glycans can be quantitatively determined by normal phase chromatography after N-glycosidase digestion and glycan labeling, for example [31]. The most prevalent N-linked glycosylation patterns at the Cy2 domain of the heavy chain (Fc) of an immunoglobulin G (IgG) are depicted in Figure 3, where the most common glycosylation of IgG is shown in section D.

![Figure 3. Common glycosylation patterns of an IgG. (A) high mannose content; (B) hybrid; (C) complex biantennary oligosaccharide with core fucosylation; (D) most prevalent oligosaccharide structures of IgG [20].](image)

Besides critical process parameters (CPP) like pH, pO\textsubscript{2} and pCO\textsubscript{2}, more often impurities play an important role in affecting CQA of the biopharmaceutical product. For example, extracellular proteases and glycosidases accumulating during the cultivation negatively influence the CQA of monoclonal antibodies [14,32–35]. The impurity spectrum consists of a multiplicity of different substances (HCP, hDNA, virus, cells, and cell debris). In this integration approach, HCPs are considered as the primary impurity based on their broad composition and range of isoelectric point (pI), molecular weight (MW), and hydrophobicity, as can be seen in Table 1 [36–40]. They exhibit no constant level, composition, or property distribution. HCPs caused by secretion or cell lysis can range in pI (2–11), MW (10–200 kDa), and variable hydrophobicity, and are therefore difficult to separate if their physicochemical properties resemble the product of interest.

| Class    | pI     | MW (kDa) | Hydrophobicity | Origin     | Cause               |
|----------|--------|----------|----------------|------------|---------------------|
| HCP      | 2–11   | 10–200   | Variable       | Host cells | Secretion, lysis    |
| hDNA     | 2–3    | 90–1000  | Low            | Host cells | Lysis               |
| Insulin  | 5.3–5.5| 5.8      | Low            | Media      | Supplement          |
| Virus    | 4–7.5  | 200–7200 | Variable       | Host cells, media | Contamination |
| Endotoxins | 1–4  | 3–40     | Variable       | Media, contamination | Contamination |
Primary recovery and purification steps for a biopharmaceutical DSP are based on physicochemical properties in order to efficiently purify the product. However, especially in the case of increasing product titers, a sub-population of impurities (i.e., HCP), which negatively affect the product quality, may remain with the desired protein and represent a certain risk [40]. Therefore, it is of critical importance to validate qualitatively and quantitatively the separation efficiency of each unit operation in the DSP.

This assessment will lead to an expanded understanding of each unit operation by classifying the impurities into “The Good, the Bad, and the Ugly”:

- Impurities, which can be separated easily from the main component, are considered “the Good.” They possess physicochemical properties significantly different from the protein of interest (i.e., pl, MW, hydrophobicity). As a result, they may be separated by only one unit operation in an efficient way (ion exchange in terms of charge differences).
- Side components showing more similarity to the product are more difficult to separate or are persistent throughout (i.e., not separable from the product) and thus are considered as “the Bad” or “the Ugly.”

By characterizing the HCP criteria for an efficient DSP, it is possible to gain a deeper understanding of the process and preserve the quality of the product. This categorization can be used for an USP DSP integration approach towards an efficient production process by circumventing the generation or accumulation of “Bad” and “Ugly” impurities (Figure 4).

The considered process for the production of monoclonal antibodies utilizes mammalian cell cultivations. Afterwards, the aqueous two-phase extraction (ATPE) is used as a cell harvesting or capture step, depending on the system composition used [41–45]. Following the ATPE, the integrated counter current chromatography (iCCC), which is a combination of an IEX and HIC, is employed as a purification and polishing step. This combination of chromatographic columns leads to a highly purified product [46].

The integration approach begins with a data-driven characterization of HCP occurring in the broth and in each unit operation. The separation efficiency is determined by analytical methods (i.e., 2D SDS-PAGE, SEC, IEX, HIC, and HPLC-MS/MS). The SEC chromatograms qualitatively describe the impurity spectrum and can be used for a determination of impurities in the molecular weight range of the considered product (150 kDa). The IEX and HIC are used for characterizing the charge and hydrophobicity of the HCPs. 2D SDS-PAGE analysis, combined with HPLC-MS/MS measurements, is used for the identification and, of utmost importance, classification of “The Good, the Bad, and the Ugly” HCPs. This classification is done by evaluating the molecular weight, isoelectric point, and hydrophobicity of the HCPs, as seen in Table 2.

Figure 4. USP DSP integration approach for a systematic development of a bioprocess.
Afterwards, these findings are used in rational process design in order to minimize or even eliminate “Ugly” HCPs, which cannot be easily separated from the product (Figure 4).

### Table 2. Analytical methods used for the characterization of HCP.

| Characteristic     | Method          | Orthogonal Method          |
|--------------------|----------------|---------------------------|
| Isoelectric point  | 2D-SDS PAGE     | IEX; HPLC-MS/MS            |
| Molecular weight   | SEC            | 2D-SDS PAGE; HPLC-MS/MS    |
| Hydrophobicity     | HIC            |                           |

One possible process design optimization procedure is the improvement of media components. Media optimization is capable of changing the broth’s HCP composition towards a population that is easier to separate or at least exhibits a lower HCP concentration. In addition, an optimized medium not only shifts the HCP profile but also improves the cell growth and product titer, which is depicted in Table 3 [47].

### Table 3. Improved parameters by using an optimized medium according to [47].

| Parameter        | Optimized medium |
|------------------|------------------|
| Titer increase   | Factor 2.5       |
| Cell growth      | Factor 2–2.3     |
| IgG/HCP          | 65%              |
| HCP profile      | Shift            |

The shifted HCP profile can be seen in the 2D-SDS PAGE comparison in Figure 5.

![Figure 5. Comparison of 2D-SDS PAGE of a reference (right) and optimized medium (left) during a CHO cultivation according to [47]. Media was improved by a three-level DoE design.](image)

In this work, the results of the characterization of the HCP profile from a mAb production process are presented. Process-related data as well as analysis-related data are used for the characterization of the process and for the classification of HCPs. The results of each analytical method are critically evaluated in order to determine a process flow being suitable for USP DSP integration and process optimization. Analytical methods such as SEC, 2D-PAGE, IEX, HIC as well as HPLC-MS/MS were used in order to identify critical HCP in the cell-free broth and during each unit operation (i.e., ATPE, IEX, and HIC).

### 2. Results and Discussion

A schematic overview of the considered alternative process as well as process- and analysis-related data are shown in Figure 6. The HCP criteria for an efficient DSP have to be evaluated for each unit operation, according to Figure 4. Here, the classification of HCP focuses on the broth, the broth after diafiltration and on a side component fraction after HIC separation. Process-related data such as titer, yield, and purity of each unit operation are shown in Table 4.
Figure 6. Schematic overview of the considered alternative process in comparison of the benchmark manufacturing route. In addition, process and analysis related data are shown and discussed in the text.
This analytical procedure focuses on the classification and characterization of HCPs. Therefore, each unit operation of the DSP has to be evaluated by its separation efficiency, using analytical methods such as 2D-SDS PAGE, IEX, HIC, and SEC to determine HCP criteria for an efficient DSP, as seen in Figure 3. Protein A and size-exclusion chromatography are used to determine yield and purity, respectively. Each unit operation was loaded with the native broth in order to determine their separation efficiency.

Table 4. Process related data of the cultivation, ATPE, and iCCC. Yield and purity were determined using protein A chromatography and SEC, respectively.

| Characteristic          | Cultivation | ATPE           | iCCC           |
|------------------------|-------------|----------------|----------------|
| System                 | Mammalian cells | PEG400/40 wt% PO4 | IEX/HIC combination |
| Titer/yield            | 6.5 g/L      | >95%           | >95%           |
| Log cell reduction     | 20.0 E6 cells/mL | 2.08          | -              |
| Purity                 | <20%         | up to 80% *    | 100%           |

* Protein-based according to SEC.

The fraction number five occurring on the HIC was chosen due to the high side component content near the target product, as seen in Figure 7. In the following, the classification of the HCPs will be performed by 2D-PAGE gels, as depicted in Figure 8.

Figure 7. Chromatograms of an analytical IEX (left) and HIC (right) measurement of the diafiltrated cell-free CHO supernatant. The vertical sections represent the number of fractions taken, representing “Good”, “Bad,” and “Ugly” impurities.

The classification criterion of the considered HCP was selected by comparing their pI and molecular weight to the target product, as seen in Table 5.

Table 5. Classification of the “Good, Bad, and Ugly” HCP in comparison to the physicochemical properties of the monoclonal antibody (mAb). MW, molecular weight; pI, isoelectric point.

| Characteristic | mAb | Good | Bad | Ugly |
|---------------|-----|------|-----|------|
| MW [kDa]      | 144.2 | <15 | >15 | >15 |
| pI [-]        | 8.30  | <4.75 | 4.75–7.30 | 7.30–9.30 |

While considering the 2D-PAGE gels, proteins with a MW lower than 15 kDa can be considered “Good” since they can be separated by using diafiltration subsequent to an ATPE with a suitable MW cutoff. Therefore, this filtration step is coupled to a buffer change, which is necessary for the use of the iCCC, since the specific light phase contains PEG400, resulting in a more viscous solution, which would make the chromatographic steps more difficult to handle.
Figure 8. 2D SDS-PAGE of the broth, diafiltrated broth (DF) and HIC fraction. Green circles represent “Good”, yellow circles “Bad,” and red circles “Ugly” HCP.

Proteins larger than 15 kDa have to be separated by another unit operation, which is based on other physicochemical properties (i.e., pI, hydrophobicity). Therefore, “Bad” and “Ugly” proteins possess a MW larger than 15 kDa. The horizontal line at 150 kDa represents the target protein in its functional condition. The vertical lines depict the isoelectric point at 4.75 and 7.0. Impurities with a pI of 4.75 can be subjected to a possible precipitation step using hydrochloric acid, which significantly reduces their concentration [42]. Those impurities exhibit a different pl than the target protein and can efficiently be separated by an IEX and are therefore classified as “Good.” Experimental IEX data show a distinctly different interaction with the stationary phase due to their surface charge distribution, as seen in Figure 9, which resemble the “Good” HCP. They elute near the void volume and can be easily separated. A similar train of thought can be conducted while characterizing the HIC chromatogram. As can be seen in Figure 9, the target product gets concentrated by each cycle in the iCCC mode.

Figure 9. Chromatograms of the IEX (left) and HIC (right) after various cycles in the iCCC mode.

Impurities with a pI range close to the target protein (i.e., 7.30–9.30) are more difficult to separate via an IEX and are therefore considered “Ugly.” However, since the separation efficiency of the IEX will depend on the column, buffer solution, and process parameters, this range can vary depending on the system used. Impurities with characteristics in between those of “Good” and “Ugly” are defined as “Bad.” They possess a pI of 4.75–7.30 and 9.30–10.00 and can be difficult to separate when other physicochemical properties (i.e., hydrophobicity) resemble the target product. This dependency can of course also occur with “Ugly” HCP but since they are already classified as difficult to separate, they will not be characterized differently. Regarding the “Good” HCP, this dependency will not occur even if other physicochemical properties show close similarity to the product, since at least one physicochemical attribute is significantly different from the target product. The pI is restricted to 10 due to the pH gradient used in the IEF prior to 2D gel electrophoresis.

The 2D-PAGE analysis seen in Figure 8 is suitable for the visualization of the side component spectrum. However, the sample preparation requires reducing agents such as DTT, which destroys the protein’s structure by reducing the disulfide bonds. This preparation procedure results in spots on the gel, which do not resemble their native structure in the supernatant. Following the aforementioned classification and separation system, proteins with a MW lower than 15 kDa but with an isoelectric point near the target product will sometimes be classified as “Good” since they can be separated by filtration. Hence, the native protein can be “Ugly” even if it appears as “Good” in the gel (assuming no change in surface charge). Thus, it is of the utmost importance to use orthogonal analytical methods.
to validate the classification. In terms of MW, SEC analysis can be conducted in order to determine the size distribution of side components, as seen in Figure 10. The advantage of using SEC analysis is the determination of the side component’s native MW distribution as well as their qualitative mass in proportion to the product’s signal. The disadvantage is the less sensitive detection of low mass content side components as well as proteins resulting in a signal overlap with the mAb.

In order to identify proteins present in the 2D-PAGE gel spots, their tryptic peptides were identified via analysis with liquid chromatography (LC) coupled to tandem mass spectrometry (MS/MS) and a database search. The numbers in the gels in Figure 8 indicate the spots that were analyzed using LC-MS/MS. The first five spots occurred in every gel. The subsequent spots were unique in each gel. The identified peptides and their corresponding proteins of each spot in these gels are presented in the appendix (Tables A1–A3). The identified proteins of the first recurrent spots are listed alongside with their MW and pI in Table 6.

As can be seen in Table 6, the MW and pI of the spots analyzed with 2D-PAGE do not correspond to the value in the protein database. This is a result of proteins existing in different species due to posttranslational modifications and proteolytic processing (proteolytic degradation and sample preparation, respectively). In contrast, the theoretically calculated pI values obtained by the ExPASy computation tool (http://web.expasy.org/compute_pi/) represent the unmodified full length amino acid sequence of a defined protein. SEC analysis, for example, is a non-invasive analytical method for the determination of MW distribution of side components, if the salt concentration used in aqueous eluents allows for separation based on molecular size exclusion alone due to the hydrodynamic radius [48]. Nevertheless, for a systematic integration approach, the classification of HCPs based on their physicochemical properties can lead to an enhanced process understanding, especially in the DSP.

![SEC chromatograms after various cycles as well as the broth after diafiltration.](image)

**Figure 10.** SEC chromatograms after various cycles as well as the broth after diafiltration.

**Table 6.** Classification of CHO proteins identified via LC-MS/MS analysis and characterized by 2D-PAGE gel. Comparison of theoretical (UniProt; pI calculated according to the amino acid sequences) and observed MW and pI with respect to the spot position on the 2D-PAGE gel.

| Spot | Gel MW | Gel pI | Class MW 1 | pI 1 | Class | Protein A0A061IN16 | UniProt Accession Number |
|------|--------|--------|------------|------|-------|-------------------|--------------------------|
| 1    | 25     | 7.0    | Bad        | 81.56| 5.69  | Bad               | Mu7-like protein          |
| 2    | 25     | 7.5    | Ugly       | 102.7| 6.02  | Bad               | Actin, cytoplasmic 1      |
| 3    | 30     | 7.6    | Ugly       | 38.03| 6.08  | Bad               | Purine nucleoside         |
| 4    | 50     | 9.4    | Bad        | 72.13| 7.23  | Ugly              | Pyruvate kinase           |
| 5    | 25     | 6.3    | Bad        | 38.03| 6.08  | Bad               | Purine nucleoside         |

1 Theoretical values according to the unmodified full length protein according to UniProt; 2 Theoretical values calculated using the ExPASy computation tool (http://web.expasy.org/compute_pi/).
3. Materials and Methods

Chinese hamster ovary cells (CHO DG44) were used for the production of a monoclonal antibody. The culture conditions were 37 °C, 5% carbon dioxide, and 130 rpm. The cultivations were carried out in shake flasks in a serum-free medium.

The ATP system applied consisted of 44.5% broth, 15.5% PEG400 (Merck KGaA, Darmstadt, Germany), and 40% of a 40 wt% phosphate buffer. All the components were weighed. The extraction was carried out at pH 6.0 in 50-mL beakers at room temperature. The system was mixed for 15 min at 140 rpm in an incubator shaker. Phase separation took place within 30 min in a separatory funnel.

The broth was diafiltered using a SARTOFLOW® Slice 200 Benchtop system from Sartorius Stedim (Germany). A 10 kDa Hydrosart® (Sartorius Stedim, Göttingen, Germany) was utilized as a membrane module.

The iCCC (integrated counter-current chromatography) is run by using Fractogel® EMD SO₃⁻(s) and Fractogel® EMD Phenyl(s) (Merck KGaA, Darmstadt, Germany). The buffers consisted of a 20 mM sodium phosphate buffer (Na₂HPO₄, NaH₂PO₄) as well as a 20 mM sodium phosphate buffer with 1 M Na₂SO₄.

The product was quantified by Protein A chromatography (PA ID Sensor Cartridge, Applied Biosystems, Bedford, MA, USA). Dulbecco’s PBS buffer (Sigma-Aldrich, St. Louis, MO, USA) was used as a loading buffer at pH 7.4 and as an elution buffer at pH 2.6. The absorbance was monitored at 280 nm.

The size exclusion chromatography was done by using a Yarra™ 3 µm SEC-3000 column (Phenomenex Ltd., Aschaffenburg, Germany) with 0.1 M Na₂SO₄, 0.1 M Na₂HPO₄, and 0.1 M NaH₂PO₄ (Merck KGaA, Germany) as a buffer system.

Isoelectric focusing was carried out using IPG strips (ReadyStrip™ IPG Strips, linear, pH 3–10, BIO-RAD, Hercules, CA, USA) and an isoelectric focusing unit of Hoefer (Hoefer Inc., Holliston, MA, USA). A subsequent SDS PAGE was carried out using gels (Criterion TGX Precast Gel, 4–15% Bis-Tris, BIO-RAD) buffers, and an electrophoresis chamber from BIO-RAD. The resulting gels were colored by Coomassie Brilliant Blue G-250 (VWR International, Radnor, PA, USA).

For the identification of proteins, selected 2D GE spots were cut out and reduced into 1-mm² pieces. After reduction of the disulfide bonds with 10 mM DL-dithiothreitol (Sigma-Aldrich) and alkylation with 50 mM iodoacetamide (Sigma-Aldrich), an in-gel proteolytic digestion was performed with 8 ng/µL trypsin (Promega, Madison, WI, USA) at 37 °C overnight. The peptides were extracted from the gel with 65% acetonitrile and 5% acetic acid in water and the solvent was evaporated to complete dryness. The peptides were re-suspended in 20 µL 0.1% formic acid (Fluka) and subjected to LC-MS/MS analysis with a nano-flow ultra-performance liquid chromatography (nano-UPLC) system (nanoACQUITY, Waters, Manchester, UK) coupled via an electrospray-ionization (ESI) source to a tandem mass spectrometer (MS/MS) consisting of a quadrupole and a orbitrap mass analyzer (Orbitrap QExactive, Thermo Scientific, Bremen, Germany). Four microliters of each sample were loaded onto a reversed-phase (RP) trapping column (Symmetry C18 Trap Column; 100 Å, 5 µm, 180 µm × 20 mm) and washed with 1% buffer B for 5 min. The peptides were eluted onto a RP capillary column (nanoAcquity Peptide BEH analytical column; 130 Å, 1.7 µm, 75 µm × 200 mm) and separated by a gradient from 3 to 35% buffer B in 35 min (250 nL/min). Eluting peptides were ionized and desorbed by ESI in the positive mode using a fused-silica emitter (I.D. 10 µm, New Objective, Woburn, MA, USA) at a capillary voltage of 1800 V. Data-dependent acquisition mode was used with the following parameters: MS level over a m/z range from 400 to 1500, with a resolution of 70,000 FWHM at m/z 200. Maximum injection time was set to 120 ms for an AGC target of 1E6. For MS/MS analysis the top 12 signals were isolated in a 2 m/z window and fragmented with a normalized HCD collision energy of 25. Fragment spectra were recorded with a resolution of 17,500 FWHM at m/z 200. Maximum injection time was set to 60 ms for an AGC target 5E5.

LC–MS raw data were processed with MaxQuant (Max Planck Institute of Biochemistry, Planegg, Germany) algorithms (version 1.5.8.3). Protein identification was carried out with Andromeda against
a hamster (*Cricetulus griseus*) ([www.uniprot.org](http://www.uniprot.org), downloaded on 31 January 2017) and a contaminant database. The searches were performed using a precursor mass tolerance set to 10 ppm and fragment mass tolerance set to 20 ppm. For peptide identification, two missed cleavages were allowed, a carbamidomethylation on the cysteine as a fixed modification and oxidation of the methionine as a variable modification. A maximum of five modifications per peptide were allowed.

**4. Conclusions**

The presented approach of integrating USP and DSP is based on the classification and characterization of impurities generated during USP. This will lead to a deeper quantitative process understanding and identification of issues in the DSP early on. Here, the HCPs were categorized into “The Good, the Bad, and the Ugly” by evaluating their physicochemical properties compared to the monoclonal antibody. In this approach “Good” impurities possess a MW lower than 15 kDa and a pI lower than 4.75. “Ugly” impurities on the other hand exhibit a pI of 7.3–9.3, whereas “Bad” impurities feature a pI between 4.75 and 7.3 as well as between 9.3 and 10.0. In order to evaluate the classification system for the generated HCPs, orthogonal analytical methods are of utmost importance. IEX and SEC analysis were conducted for the identification of impurities. Theoretical pI and MW calculated based on the amino acid sequence differ from the experimental values obtained in 2D gel electrophoresis. This is due to not considering posttranslational modifications, as well as in vivo and ex vivo proteolytic processing.

Nevertheless, it is possible to characterize HCP based on pI and MW properties. In order to fully categorize the separation efficiency of each unit operation in the DSP as well as of their combinations, the HCP profile has to be determined with the aforementioned analytical methods in future approaches. This portfolio can of course be extended by adding supplementary methods like NMR technologies, preferably online [49].

Considering the significant amount of work in terms of characterization, monitoring, and removal of impurities and contaminations created by the USP step, as well as the time and cost associated with their removal, it may be worthwhile to reflect in more detail how these impurities and product variations are generated in the first place. Work to this end already started some time ago. Initial results and corresponding concepts for a more balanced integrated process design will be presented in the near future.

**Acknowledgments:** The authors would especially like to acknowledge Petra Gronemeyer (now Boehringer/Biberach) for her outstanding contribution to this topic during her PhD studies, for which she has been highly esteemed at conferences.

**Author Contributions:** Martin Kornecki conceived and designed the experiment as well as wrote the paper. Martin Kornecki performed the SDS-PAGE experiments. Fabian Mestmäcker performed the chromatographic (iCCC, IEX, HIC) experiments. Laura Heikaus de Figueiredo performed the LC-MS/MS experiments and analyzed the data. All mentioned authors interpreted the data. Hartmut Schlüter as well as Jochen Strube substantively revised the work and contributed the materials and analysis tools. Jochen Strube is responsible for conception and supervision.

**Conflicts of Interest:** The authors declare no conflict of interest.
## Appendix A

Table A1. Peptides and their corresponding proteins identified via LC-MS/MS in spots of 2D gel of the broth. Molecular weight (MW) and isoelectric point (pI) of the unmodified full length protein according to UniProt.

| #  | Gel MW | Gel pI | MW (UniProt) | pI (UniProt) | Primary Accession Number (UniProt) | Number of Unique Peptides | Protein                              |
|----|--------|--------|--------------|--------------|-----------------------------------|---------------------------|--------------------------------------|
| 1  | 25     | 7.2    | 25.76        | 6.45         | A0A061H1Z2                        | 9                         | Platelet-activating factor           |
|    |        |        | 81.56        | 5.69         | A0A061JN16                        | 11                        | Glutathione S-transferase Mu 7-like protein |
|    |        |        | 81.56        | 5.69         | A0A061HYZ1                        | 9                         | Peroxiredoxin-6-like protein         |
| 2  | 25     | 7.9    | 30.28        | 7.22         | A0A061RFC9                        | 4                         | Carbonic anhydrase                   |
|    |        |        | 89.52        | 6.23         | A0A061JJC4                        | 4                         | Glutathione S-transferase Mu 1-like protein |
|    |        |        | 81.56        | 5.69         | A0A061JN16                        | 4                         | Glutathione S-transferase Mu 7-like protein |
| 3  | 30     | 7.6    | 72.13        | 7.23         | A0A098KXF7                        | 8                         | Pyruvate kinase                     |
|    |        |        | 38.03        | 6.08         | A0A061ILE8                        | 6                         | Purine nucleoside phosphorylase-like protein |
|    |        |        | 32.23        | 9.11         | A0A061IAK4                        | 5                         | 1-lactate dehydrogenase A chain      |
| 4  | 50     | 9.6    | 45.28        | 8.48         | A0A061IB69                        | 7                         | Fructose-bisphosphate aldolase       |
|    |        |        | 72.13        | 7.23         | A0A098KXF7                        | 15                        | Pyruvate kinase                     |
|    |        |        | 102.7        | 6.02         | A0A069C7Y3                        | 5                         | Actin, cytoplasmic 1                 |
| 5  | 25     | 6.6    | 27.39        | 6.34         | A0A061IE1                         | 8                         | Proteasome subunit                   |
|    |        |        | 89.52        | 6.23         | A0A061JJC4                        | 8                         | Glutathione S-transferase Mu 1-like protein |
|    |        |        | 81.56        | 5.69         | A0A061JN16                        | 8                         | Glutathione S-transferase Mu 7-like protein |
| 6  | 45     | 6.7    | 50.57        | 5.93         | G3GR73                            | 11                        | Rab-GDP diss. inhib                  |
|    |        |        | 52.79        | 6            | A0A098KB71                        | 10                        | Cytosol aminopeptidase-like protein  |
|    |        |        | 44.67        | 7.54         | A0A061I88                         | 9                         | Alpha-enolase                        |
| 7  | 50     | 6.1    | 52.79        | 6            | A0A098KB1                         | 20                        | Aminopeptidase                      |
|    |        |        | 72.13        | 7.23         | A0A098KXF7                        | 29                        | Pyruvate kinase                     |
|    |        |        | 145.1        | 8.37         | A0A061H29                         | 15                        | Glucose-6-phosphate 1-dehydrogenase  |
| 8  | 57     | 6      | 73.86        | 5.56         | A0A061ISD1                        | 22                        | Heat shock protein                   |
|    |        |        | 74.72        | 5.29         | A0A061H8C7                        | 9                         | Plastin-3                            |
|    |        |        | 69.64        | 5.57         | A0A061FSU1                        | 9                         | Heat shock-related protein 2         |
|    |        |        | 72.13        | 7.23         | A0A098KXF7                        | 11                        | Pyruvate kinase                     |
|    |        |        | 117.7        | 5.42         | G3BRG1                            | 8                         | Ubiquitin activating enzyme E1       |
|    |        |        | 73.86        | 5.56         | A0A061ISD1                        | 7                         | Heat shock protein                   |
|    |        |        | 68.43        | 5.55         | A0A061IQ2                         | 5                         | Heat shock protein                   |
|    |        |        | 85.71        | 5.2          | A0A061IA66                        | 5                         | Vitamin K-dependent protein S        |
|    |        |        | 85.71        | 5.55         | A0A061IQ2                         | 5                         | Dipeptidyl peptidase 3              |
| 9  | 80     | 6.1    | 73.86        | 5.56         | A0A061ISD1                        | 9                         | Heat shock protein                   |
|    |        |        | 72.13        | 7.23         | A0A098KXF7                        | 11                        | Pyruvate kinase                     |
|    |        |        | 89.52        | 6.23         | A0A061JJC4                        | 19                        | Glutathione S-transferase Mu 1-like protein |
|    |        |        | 81.56        | 5.69         | A0A061JN16                        | 14                        | Glutathione S-transferase Mu 7-like protein |
| 10 | 70     | 5.6    | 73.86        | 5.56         | A0A061ISD1                        | 37                        | Pyruvate kinase                     |
|    |        |        | 68.43        | 5.55         | A0A061IQ2                         | 10                        | Cytosol aminopeptidase-like protein  |
|    |        |        | 85.71        | 5.2          | A0A061IA66                        | 4                         | Heat shock protein                   |
|    |        |        | 85.71        | 5.55         | A0A061IQ2                         | 4                         | Cytosol aminopeptidase-like protein  |
| 11 | 25     | 6      | 25.88        | 6.43         | A0A061HYZ1                        | 9                         | Peroxiredoxin                       |
|    |        |        | 89.52        | 6.23         | A0A061JJC4                        | 19                        | Glutathione S-transferase Mu 1-like protein |
|    |        |        | 81.56        | 5.69         | A0A061JN16                        | 14                        | Glutathione S-transferase Mu 7-like protein |
| 12 | 55     | 7.8    | 72.13        | 7.23         | A0A098KXF7                        | 37                        | Pyruvate kinase                     |
|    |        |        | 52.79        | 6            | A0A098KB1                         | 10                        | Cytosol aminopeptidase-like protein  |
|    |        |        | 52.79        | 6            | A0A098KB1                         | 4                         | Heat shock protein                   |
|    |        |        | 145.1        | 8.37         | A0A061H29                         | 2                         | Glucose-6-phosphate 1-dehydrogenase  |
| 13 | 50     | 8.6    | 52.79        | 6            | A0A098KB1                         | 4                         | Pyruvate kinase                     |
|    |        |        | 72.13        | 7.23         | A0A098KXF7                        | 19                        | Cytosol aminopeptidase-like protein  |
|    |        |        | 44.67        | 7.54         | A0A061I88                         | 3                         | Eukaryotic translation initiation factor 2 subunit 3-like protein |
Table A2. Peptides and their corresponding proteins identified via LC-MS/MS in spots of 2D gel of the diafiltered broth. Molecular weight (MW) and isoelectric point (pI) of the unmodified full length protein according to UniProt.

| # | Gel MW | Gel pI | MW (UniProt) | pI (UniProt) | Primary accession number (UniProt) | Number of Unique Peptides | Protein |
|---|--------|--------|--------------|-------------|----------------------------------|--------------------------|---------|
| 1 | 25     | 7      | 26.96        | 5.38        | A0A061H6A0                        | 5                        | Glutathione S-transferase A4-like protein |
|   | 81.56  | 5.69   | 81.56        | 5.69        | A0A061IN16                        | 8                        | Glutathione S-transferase Mu 7-like protein |
|   | 38.03  | 6.08   | 38.03        | 6.08        | A0A061IJG8                        | 8                        | Purine nucleoside phosphorylase-like protein |
| 2 | 25     | 7.5    | 38.03        | 6.08        | A0A061IJG8                        | 6                        | Purine nucleoside phosphorylase |
|   | 81.56  | 5.69   | 81.56        | 5.69        | A0A061IN16                        | 8                        | Glutathione S-transferase Mu 7-like protein |
|   | 38.03  | 6.08   | 38.03        | 6.08        | A0A061IJG8                        | 8                        | Purine nucleoside phosphorylase-like protein |
|   | 102.7  | 6.02   | 102.7        | 6.02        | A0A069C7Y3                        | 2                        | Actin, cytoplasmic 1 |
|   | 43.35  | 6.48   | 43.35        | 6.48        | A0A061HJG8                        | 2                        | Prostaglandin reductase 1-like protein |
|   | 89.52  | 6.23   | 89.52        | 6.23        | A0A061HJG8                        | 2                        | Fructose-bisphosphate aldolase |
|   | 43.35  | 6.48   | 43.35        | 6.48        | A0A061HJG8                        | 2                        | Fructose-bisphosphate aldolase |
|   | 361.89 | 4.81   | 361.89       | 4.81        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
|   | 138.68 | 6.78   | 138.68       | 6.78        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
|   | 11.37  | 11.36  | 11.37        | 11.36       | G3H2T6                            | 4                        | Histone H4 |
|   | 128.68 | 6.78   | 128.68       | 6.78        | A0A061HJG8                        | 3                        | Exosome component 10 isoform 1 |
| 3 | 30     | 7      | 38.03        | 6.08        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
| 4 | 50     | 9.4    | 38.03        | 6.08        | A0A061HJG8                        | 7                        | Desmoglein-4-like protein |
| 5 | 25     | 6.6    | 38.03        | 6.08        | A0A061HJG8                        | 7                        | Desmoglein-4-like protein |
| 6 | 37     | 9.4    | 38.03        | 6.08        | A0A061HJG8                        | 7                        | Desmoglein-4-like protein |
| 7 | 30     | 7      | 38.03        | 6.08        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
| 8 | 30     | 6.8    | 38.03        | 6.08        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
| 9 | 17     | 6.6    | 11.37        | 11.36       | G3H2T6                            | 4                        | Desmoglein-4-like protein |
| 10| 30     | 5.6    | 52.25        | 5.35        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
|   | 50.99  | 6.94   | 50.99        | 6.94        | A0A061HJG8                        | 3                        | Histone H4 |
| 11| 30     | 4.5    | 52.25        | 5.35        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
| 12| 30     | 2.8    | 38.03        | 6.08        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
| 13| 15     | 6.7    | 38.03        | 6.08        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
|   | 43.35  | 6.48   | 43.35        | 6.48        | A0A061HJG8                        | 2                        | Desmoglein-4-like protein |
|   | 89.52  | 6.23   | 89.52        | 6.23        | A0A061HJG8                        | 5                        | Desmoglein-4-like protein |
|   | 361.89 | 4.81   | 361.89       | 4.81        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
|   | 138.68 | 6.78   | 138.68       | 6.78        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
| 14| 15     | 6.1    | 38.03        | 6.08        | A0A061HJG8                        | 5                        | Desmoglein-4-like protein |
| 15| 12     | 5.6    | 17.16        | 7.8         | A0A061HJG8                        | 5                        | Desmoglein-4-like protein |
| 16| 17     | 6.6    | 17.19        | 5.94        | A0A061HJG8                        | 4                        | Desmoglein-4-like protein |
|   | 23.42  | 5.1    | 23.42        | 5.1         | G3H2T6                            | 3                        | SH3 binding protein |
|   | 89.52  | 6.23   | 89.52        | 6.23        | A0A061HJG8                        | 8                        | Glutathione S-transferase |
|   | 102.7  | 6.02   | 102.7        | 6.02        | A0A061HJG8                        | 2                        | Actin, cytoplasmic 1 |
| 17| 16     | 9.2    | 14.73        | 9.87        | A0A061HJG8                        | 3                        | Ubiquitin-60S |
|   | 102.7  | 6.02   | 102.7        | 6.02        | A0A061HJG8                        | 3                        | Ubiquitin-60S |
|   | 23.42  | 5.1    | 23.42        | 5.1         | G3H2T6                            | 3                        | Ubiquitin-60S |

Antibodies 2017, 6, 13
Table A3. Peptides and their corresponding proteins identified via LC-MS/MS in spots of 2D gel of the HIC fraction. Molecular weight (MW) and isoelectric point (pI) of the unmodified full length protein according to UniProt.

| #  | Gel MW | Gel pI | MW (UniProt) | pl (UniProt) | Primary Accession Number (UniProt) | Number of Unique Peptides | Protein                                           |
|----|--------|--------|--------------|--------------|------------------------------------|--------------------------|---------------------------------------------------|
| 1  | 25     | 6.9    | -            | -            | G3H2T6                             | -                       | Histone H4                                        |
| 2  | 25     | 7.6    | 11.37        | 11.36        | A0A069C7Y3                         | 2                       | Actin, cytoplasmic 1                               |
|    |        |        | 102.7        | 6.02         | A0A061ILE8                         | 2                       | Purine nucleoside                                 |
|    |        |        | A0A069C7Y3   | 11.36        |                                    |                          |                                                   |
| 3  | 30     | 7.6    | 38.03        | 6.08         | A0A061ILE8                         | 2                       | Actin, cytoplasmic 1                               |
|    |        |        | 102.7        | 6.02         | A0A069C7Y3                         | 1                       | Purine nucleoside                                 |
|    |        |        | A0A061IJI8   | 7.54         |                                    | 8                       | Alpha-enolase                                     |
|    |        |        | 44.67        | 7.54         |                                    | 8                       | Pyruvate kinase                                   |
|    |        |        | 72.13        | 7.23         | A0A098KX7F7                        | 8                       |                                                   |
| 4  | 50     | 8.4    | 44.67        | 7.54         | A0A061IJI8                         | 8                       | Actin, cytoplasmic 1                               |
|    |        |        | 72.13        | 7.23         | A0A098KX7F7                        | 8                       | Purine nucleoside                                 |
|    |        |        | 38.03        | 6.08         | A0A061ILE8                         | 2                       | Pyruvate kinase                                   |
|    |        |        | 102.7        | 6.02         | A0A061ILE8                         | 6                       | Purine nucleoside                                 |
|    |        |        | A0A069C7Y3   | 11.36        |                                    |                          |                                                   |
| 5  | 25     | 6.3    | 38.03        | 6.08         | A0A061ILE8                         | 4                       | Purine nucleoside                                 |
| 6  | 25     | 8.4    | 38.03        | 6.08         | A0A061ILE8                         | 4                       | Purine nucleoside                                 |
| 7  | 50     | 7.6    | 44.67        | 7.54         | A0A061IJI8                         | 1                       | Actin, cytoplasmic 1                               |
|    |        |        | 102.7        | 6.02         | A0A069C7Y3                         | 3                       | Alpha-enolase                                     |
|    |        |        | 44.67        | 7.54         | A0A061IJI8                         | 5                       | Actin, cytoplasmic 1                               |
|    |        |        | 72.13        | 7.23         | A0A098KX7F7                        | 2                       | Pyruvate kinase                                   |
|    |        |        | 72.13        | 7.23         | A0A098KX7F7                        | 2                       |                                                   |
| 8  | 47     | 7.6    | 59.76        | 9.22         | A0A061ICE4                         | 4                       | ATP synthase subunit                               |
|    |        |        | 14.73        | 9.87         | A0A061IQB8                         | 2                       | Ubiquitin-60S ribosomal protein L40-like isoform 2 |
|    |        |        | 102.7        | 6.02         | A0A061IQB8                         | 2                       | Actin, cytoplasmic 1                               |
|    |        |        | A0A061C7Y3   | 5.42         |                                    | 2                       |                                                   |
| 9  | 50     | 7.2    | 211.66       | 5.42         | A0A0614N6                          | 1                       | CAP-Gly domain-containing linker protein 1        |
| 10 | 25     | 5.1    | -            | -            | -                                  | -                       | -                                                |
| 11 | 50     | 4.8    | 211.66       | 5.42         | A0A0614N6                          | 1                       | CAP-Gly domain-containing linker protein 1        |
| 12 | 52     | 4      | -            | -            | -                                  | -                       | -                                                |

(-) Spots, which were not able to be identified.
References

1. EvaluatePharma. World Preview 2016, Outlook to 2022; EvaluatePharma: London, UK, 2016; pp. 1–39.
2. EvaluatePharma. World Preview 2015, Outlook to 2020; EvaluatePharma: London, UK, 2015; pp. 1–39.
3. Li, F.; Vijayasankaran, N.; Shen, A.; Kiss, R.; Amanullah, A. Cell culture processes for monoclonal antibody production. mAbs 2010, 2, 466–479. [CrossRef] [PubMed]
4. Gronemeyer, P.; Ditz, R.; Strube, J. Trends in Upstream and Downstream Process Development for Antibody Manufacturing. Bioengineering 2014, 1, 188–212. [CrossRef]
5. Sommerfeld, S.; Strube, J. Challenges in biotechnology production—Generic processes and process optimization for monoclonal antibodies. Chem. Eng. Process. Process Intensif. 2005, 44, 1123–1137. [CrossRef]
6. Birch, J.R.; Racher, A.J. Antibody production. Adv. Drug Deliv. Rev. 2006, 58, 671–685. [CrossRef] [PubMed]
7. Liu, H.F.; Ma, J.; Winter, C.; Bayer, R. Recovery and purification process development for monoclonal antibody production. mAbs 2010, 2, 480–499. [CrossRef] [PubMed]
8. Shukla, A.A.; Thömmes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28, 253–261. [CrossRef] [PubMed]
9. Jain, E.; Kumar, A. Upstream processes in antibody production: Evaluation of critical parameters. Biotechnol. Adv. 2008, 26, 46–72. [CrossRef] [PubMed]
10. Strube, J.; Grote, F.; Josch, J.P.; Ditz, R. Process development and design of downstream processes. Chemie-Ingenieur-Technik 2011, 83, 1044–1065. [CrossRef]
11. Gagnon, P. Technology trends in antibody purification. J. Chromatogr. A 2012, 1221, 57–70. [CrossRef] [PubMed]
12. Kelley, B. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. mAbs 2009, 1, 440–449. [CrossRef]
13. Chon, J.H.; Zarbis-Papastoitsis, G. Advances in the production and downstream processing of antibodies. New Biotechnol. 2011, 28, 458–463. [CrossRef] [PubMed]
14. Park, J.H.; Jin, J.H.; Lim, M.S.; An, H.J.; Kim, J.W.; Lee, G.M. Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells. Sci. Rep. 2017, 7, 44246. [CrossRef] [PubMed]
15. Reinhart, D.; Damjanovic, L.; Kaisermayer, C.; Kunert, R. Benchmarking of commercially available CHO cell culture media for antibody production. Appl. Microbiol. Biotechnol. 2015, 4645–4657. [CrossRef] [PubMed]
16. Strube, J.; Sommerfeld, S.; Lohrmann, M. Process Development and Optimization for Biotechnology Production—Monoclonal Antibodies. In Bioseparation and Bioprocessing, 2nd ed.; Subramanian, G., Ed.; Wiley-VCH: Weinheim, Germany, 2007.
17. Strube, J.; Grote, F.; Ditz, R. Bioprocess Design and Production Technology for the Future. In Biopharmaceutical Production Technology; Subramanian, G., Ed.; Wiley-VCH: Weinheim, Germany, 2012.
18. GE Healthcare. Strategies for Protein Purification. Handbook; GE Healthcare: Little Chalfont, UK, 2010.
19. Levy, N.E.; Valente, K.N.; Choe, L.H.; Lee, K.H.; Lenhoff, A.M. Identification and Characterization of Host Cell Protein Product-Associated Impurities in Monoclonal Antibody Bioprocessing. Biotechnol. Bioeng. 2014, 111, 904–912. [CrossRef] [PubMed]
20. Del Val, I.J.; Kontoravdi, C.; Nagy, J.M. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol. Prog. 2010, 26, 1505–1527. [CrossRef] [PubMed]
21. Hinz, D.C. Process analytical technologies in the pharmaceutical industry: The FDA’s PAT initiative. Anal. Bioanal. Chem. 2006, 384, 1036–1042. [CrossRef] [PubMed]
22. Mercier, S.M.; Rouel, P.M.; Lebrun, P.; Diepenbroek, B.; Wijffels, R.H.; Streefland, M. Process analytical technology tools for perfusion cell culture. Eng. Life Sci. 2016, 16, 25–35. [CrossRef]
23. Hakemeyer, C.; McNight, N.; St. John, R.; Meier, S.; Trexler-Schmidt, M.; Kelley, B.; Zettl, F.; Puskeiler, R.; Kleinjans, A.; Lim, F.; et al. Process characterization and Design Space definition. Biologicals 2016, 44, 306–318. [CrossRef] [PubMed]
24. Frenzel, A.; Hust, M.; Schirrmann, T. Expression of recombinant antibodies. Front. Immunol. 2013, 4, 1–20. [CrossRef] [PubMed]
Antibodies 2017, 6, 13

25. Shields, R.L.; Lai, J.; Keck, R.; O’Connell, L.Y.; Hong, K.; Gloria Meng, Y.; Weikert, S.H.A.; Presta, L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fe\gammaRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277, 26733–26740. [CrossRef] [PubMed]

26. Richter, V.; Kwiatkowski, M.; Omidi, M.; Omidi, A.; Robertson, W.D.; Schlüter, H. Mass spectrometric analysis of protein species of biologics. Pharm. Bioprocess. 2013, 1, 381–404. [CrossRef]

27. Hakemeyer, C.; Pech, M.; Lipok, G.; Herrmann, A. Characterization of the influence of cultivation parameters on extracellular modifications of antibodies during fermentation. BMC Proc. 2013, 7, P85. [CrossRef]

28. Kunert, R.; Reinhart, D. Advances in recombinant antibody manufacturing. Appl. Microbiol. Biotechnol. 2016, 100, 3451–3461. [CrossRef] [PubMed]

29. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nature reviews. Drug Discovery 2009, 8, 226–234. [CrossRef] [PubMed]

30. Alt, N.; Zhang, T.Y.; Motchnik, P.; Taticek, R.; Quarmby, V.; Schlothauer, T.; Beck, H.; Emrich, T.; Harris, R.J. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 2016, 44, 1–15. [CrossRef] [PubMed]

31. Brunner, M.; Fricke, J.; Kroll, P.; Herwig, C. Investigation of the interactions of critical scale-up parameters (pH, pO2 and pCO2) on CHO batch performance and critical quality attributes. Bioprocess Biosyst. Eng. 2016, 1–13. [CrossRef] [PubMed]

32. Chee Furng Wong, D.; Tin Kam Wong, K.; Tang Goh, L.; Kiat Heng, C.; Gek Sim Yap, M. Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol. Bioeng. 2005, 89, 164–177. [CrossRef] [PubMed]

33. Gao, S.X.; Zhang, Y.; Stansberry-Perkins, K.; Buko, A.; Bai, S.; Nguyen, V.; Brader, M.L. Fragmentation of a highly pure monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol. Bioeng. 2011, 108, 972–982. [CrossRef] [PubMed]

34. Gramer, M.J.; Goochee, C.F. Glycosidase activities of the 293 and NS0 cell lines, and of an antibody-producing hybridoma cell line. Biotechnol. Bioeng. 1994, 43, 423–428. [CrossRef] [PubMed]

35. Robert, F.; Bierau, H.; Rossi, M.; Agugiaro, D.; Soranzo, T.; Broly, T.; Mitchell-Logean, C. Degradation of an Fc-fusion recombinant protein by host cell proteases: Identification of a CHO cathepsin D protease. Biotechnol. Bioeng. 2009, 104, 1132–1141. [CrossRef] [PubMed]

36. Tait, A.S.; Hogwood, C.E.M.; Smales, C.M.; Bracewell, D.G. Host cell protein dynamics in the supernatant of a mAb producing CHO cell line. Biotechnol. Bioeng. 2012, 109, 971–982. [CrossRef] [PubMed]

37. Hogwood, C.E.M.; Tait, A.S.; Koloteva-Levine, N.; Bracewell, D.G.; Smales, C.M. The dynamics of the CHO host cell protein profile during clarification and protein A capture in a platform antibody purification process. Biotechnol. Bioeng. 2013, 110, 240–251. [CrossRef] [PubMed]

38. Singh, N.; Arunkumar, A.; Chollangi, S.; Tan, Z.G.; Borys, M.; Li, Z.J. Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives. Biotechnol. Bioeng. 2016, 113, 698–716. [CrossRef] [PubMed]

39. Valente, K.N.; Lenhoff, A.M.; Lee, K.H. Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing. Biotechnol. Bioeng. 2015, 112, 1232–1242. [CrossRef] [PubMed]

40. Wang, X.; Hunter, A.K.; Mozier, N.M. Host cell proteins in biologics development: Identification, quantitation and risk assessment. Biotechnol. Bioeng. 2009, 103, 446–458. [CrossRef] [PubMed]

41. Eggersgluess, J.K.; Richter, M.; Dieterle, M.; Strube, J. Multi-stage aqueous two-phase extraction for the purification of monoclonal antibodies. Chem. Eng. Technol. 2014, 37, 675–682. [CrossRef]

42. Grommeyer, P.; Ditz, R.; Strube, J. Implementation of aqueous two-phase extraction combined with precipitation in a monoclonal antibody manufacturing process. Chimica Oggi/Chem. Today 2016, 34, 66–70.

43. Eggersgluess, J.A.N.K.; Both, S.; Strube, J. Process Development for the Extraction of Biomolecules. Chimica Oggi/Chem. Today 2012, 30, 4.

44. Asenjo, J.A.; Andrews, B.A. Aqueous two-phase systems for protein separation: A perspective. J. Chromatogr. A 2011, 1218, 8826–8835. [CrossRef] [PubMed]

45. Azevedo, A.M.; Gomes, A.G.; Rosa, P.A.J.; Ferreira, I.F.; Pisco, A.M.M.O.; Aires-Barros, M.R. Partitioning of human antibodies in polyethylene glycol-sodium citrate aqueous two-phase systems. Sep. Purif. Technol. 2009, 65, 14–21. [CrossRef]
46. Zobel, S.; Helling, C.; Ditz, R.; Strube, J. Design and operation of continuous countercurrent chromatography in biotechnological production. *Ind. Eng. Chem. Res.* **2014**, *53*, 9169–9185. [CrossRef]

47. Gronemeyer, P.; Ditz, R.; Strube, J. DoE based integration approach of upstream and downstream processing regarding HCP and ATPE as harvest operation. *Biochem. Eng. J.* **2016**, *113*, 158–166. [CrossRef]

48. Ahmed, U.; Saunders, G. The Effect of NaCl Concentration on Protein Size Exclusion Chromatography. Application Note. Available online: http://cn.agilent.com/cs/library/applications/SI-02416.pdf (accessed on 17 July 2017).

49. Roch, P.; Mandenius, C.-F. On-line monitoring of downstream bioprocesses. *Curr. Opin. Chem. Eng.* **2016**, *14*, 112–120. [CrossRef]